118 related articles for article (PubMed ID: 14980648)
1. New heteroarylbenzenesulphonamides as matrix metalloproteinase inhibitors.
Delbecq F; Cordonnier G; Pommery N; Barbry D; Hénichart JP
Bioorg Med Chem Lett; 2004 Mar; 14(5):1119-21. PubMed ID: 14980648
[TBL] [Abstract][Full Text] [Related]
2. QSAR analysis of some 5-amino-2-mercapto-1,3,4-thiadiazole based inhibitors of matrix metalloproteinases and bacterial collagenase.
Jamloki A; Karthikeyan C; Hari Narayana Moorthy NS; Trivedi P
Bioorg Med Chem Lett; 2006 Jul; 16(14):3847-54. PubMed ID: 16682189
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and preliminary biological evaluation of new radioiodinated MMP inhibitors for imaging MMP activity in vivo.
Kopka K; Breyholz HJ; Wagner S; Law MP; Riemann B; Schröer S; Trub M; Guilbert B; Levkau B; Schober O; Schäfers M
Nucl Med Biol; 2004 Feb; 31(2):257-67. PubMed ID: 15013492
[TBL] [Abstract][Full Text] [Related]
4. Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1.
Reiter LA; Robinson RP; McClure KF; Jones CS; Reese MR; Mitchell PG; Otterness IG; Bliven ML; Liras J; Cortina SR; Donahue KM; Eskra JD; Griffiths RJ; Lame ME; Lopez-Anaya A; Martinelli GJ; McGahee SM; Yocum SA; Lopresti-Morrow LL; Tobiassen LM; Vaughn-Bowser ML
Bioorg Med Chem Lett; 2004 Jul; 14(13):3389-95. PubMed ID: 15177439
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors.
Zhang YM; Fan X; Xiang B; Chakravarty D; Scannevin R; Burke S; Karnachi P; Rhodes K; Jackson P
Bioorg Med Chem Lett; 2006 Jun; 16(12):3096-100. PubMed ID: 16632358
[TBL] [Abstract][Full Text] [Related]
6. A novel series of highly selective inhibitors of MMP-3.
Whitlock GA; Dack KN; Dickinson RP; Lewis ML
Bioorg Med Chem Lett; 2007 Dec; 17(24):6750-3. PubMed ID: 18029177
[TBL] [Abstract][Full Text] [Related]
7. NMR solution structure of the catalytic fragment of human fibroblast collagenase complexed with a sulfonamide derivative of a hydroxamic acid compound.
Moy FJ; Chanda PK; Chen JM; Cosmi S; Edris W; Skotnicki JS; Wilhelm J; Powers R
Biochemistry; 1999 Jun; 38(22):7085-96. PubMed ID: 10353819
[TBL] [Abstract][Full Text] [Related]
8. Role of sulfonamide group in matrix metalloproteinase inhibitors.
Cheng XC; Wang Q; Fang H; Xu WF
Curr Med Chem; 2008; 15(4):368-73. PubMed ID: 18288991
[TBL] [Abstract][Full Text] [Related]
9. Amber force field implementation, molecular modelling study, synthesis and MMP-1/MMP-2 inhibition profile of (R)- and (S)-N-hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-3-methylbutanamides.
Tuccinardi T; Martinelli A; Nuti E; Carelli P; Balzano F; Uccello-Barretta G; Murphy G; Rossello A
Bioorg Med Chem; 2006 Jun; 14(12):4260-76. PubMed ID: 16483784
[TBL] [Abstract][Full Text] [Related]
10. Novel matrix metalloproteinase inhibitors derived from quinoxalinone scaffold (Part I).
Li Y; Zhang J; Xu W; Zhu H; Li X
Bioorg Med Chem; 2010 Feb; 18(4):1516-25. PubMed ID: 20097082
[TBL] [Abstract][Full Text] [Related]
11. Novel matrix metalloproteinase inhibitors: generation of lead compounds by the in silico fragment-based approach.
Takahashi K; Ikura M; Habashita H; Nishizaki M; Sugiura T; Yamamoto S; Nakatani S; Ogawa K; Ohno H; Nakai H; Toda M
Bioorg Med Chem; 2005 Jul; 13(14):4527-43. PubMed ID: 15908222
[TBL] [Abstract][Full Text] [Related]
12. Novel fluorinated derivatives of the broad-spectrum MMP inhibitors N-hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](benzyl)- and (3-picolyl)-amino]-3-methyl-butanamide as potential tools for the molecular imaging of activated MMPs with PET.
Wagner S; Breyholz HJ; Law MP; Faust A; Höltke C; Schröer S; Haufe G; Levkau B; Schober O; Schäfers M; Kopka K
J Med Chem; 2007 Nov; 50(23):5752-64. PubMed ID: 17956082
[TBL] [Abstract][Full Text] [Related]
13. Development of a receptor-based 3D-QSAR study for the analysis of MMP2, MMP3, and MMP9 inhibitors.
Tuccinardi T; Nuti E; Ortore G; Rossello A; Avramova SI; Martinelli A
Bioorg Med Chem; 2008 Aug; 16(16):7749-58. PubMed ID: 18640045
[TBL] [Abstract][Full Text] [Related]
14. A new role for old ligands: discerning chelators for zinc metalloproteinases.
Jacobsen FE; Lewis JA; Cohen SM
J Am Chem Soc; 2006 Mar; 128(10):3156-7. PubMed ID: 16522091
[TBL] [Abstract][Full Text] [Related]
15. New beginnings for matrix metalloproteinase inhibitors: identification of high-affinity zinc-binding groups.
Puerta DT; Lewis JA; Cohen SM
J Am Chem Soc; 2004 Jul; 126(27):8388-9. PubMed ID: 15237990
[TBL] [Abstract][Full Text] [Related]
16. A 18F-radiolabeled analogue of CGS 27023A as a potential agent for assessment of matrix-metalloproteinase activity in vivo.
Breyholz HJ; Wagner S; Levkau B; Schober O; Schäfers M; Kopka K
Q J Nucl Med Mol Imaging; 2007 Mar; 51(1):24-32. PubMed ID: 17372570
[TBL] [Abstract][Full Text] [Related]
17. Sultam hydroxamates as novel matrix metalloproteinase inhibitors.
Cherney RJ; Mo R; Meyer DT; Hardman KD; Liu RQ; Covington MB; Qian M; Wasserman ZR; Christ DD; Trzaskos JM; Newton RC; Decicco CP
J Med Chem; 2004 Jun; 47(12):2981-3. PubMed ID: 15163180
[TBL] [Abstract][Full Text] [Related]
18. Advances in matrix metalloproteinase inhibitors based on pyrrolidine scaffold.
Cheng XC; Wang Q; Fang H; Xu WF
Curr Med Chem; 2008; 15(4):374-85. PubMed ID: 18288992
[TBL] [Abstract][Full Text] [Related]
19. A new 18F-labelled derivative of the MMP inhibitor CGS 27023A for PET: radiosynthesis and initial small-animal PET studies.
Wagner S; Breyholz HJ; Höltke C; Faust A; Schober O; Schäfers M; Kopka K
Appl Radiat Isot; 2009 Apr; 67(4):606-10. PubMed ID: 19167232
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and in vitro evaluation of targeted tetracycline derivatives: effects on inhibition of matrix metalloproteinases.
Vidal A; Sabatini M; Rolland-Valognes G; Renard P; Madelmont JC; Mounetou E
Bioorg Med Chem; 2007 Mar; 15(6):2368-74. PubMed ID: 17267227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
